



## Eli Lilly's Announcement Regarding Oral GLP-1 Orforglipron (Results of Phase III ACHIEVE-3 Trial for Type 2 Diabetes)

TOKYO, February 26, 2026 -- [Chugai Pharmaceutical Co., Ltd.](#) (hereafter "Chugai", TOKYO: 4519) announced that [Eli Lilly and Company](#) (hereafter "Eli Lilly", NYSE: LLY) issued a news release on February 26, 2026 (local time) regarding positive full results from the Phase 3 ACHIEVE-3 trial of orforglipron. Orforglipron was discovered by Chugai, and Eli Lilly holds its exclusive development and commercialization rights.

For the full text of Eli Lilly's news release, please refer to the Latest News via the following link:

Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in *The Lancet*

<https://investor.lilly.com/>

###